Advances in the treatment of polymyalgia rheumatica and giant cell arteritis

Nature Reviews Rheumatology, Published online: 08 January 2024; doi:10.1038/s41584-023-01069-2Research published in 2023 has demonstrated the efficacy of sarilumab for IL-6 blockade in polymyalgia rheumatica and of secukinumab for IL-17 blockade in giant cell arteritis (GCA). Furthermore, preliminary results with human monocyte-derived suppressive cells suggest the potential of cellular therapeutics for the treatment of GCA.
Source: Nature Reviews Rheumatology - Category: Rheumatology Authors: Source Type: research